Compare Eli Lilly And Co (LLY) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Williams-Sonoma, Inc. — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Williams-Sonoma, Inc. trades at $241.78 (market cap $28.15B). The key difference: Eli Lilly And Co is far larger — about 36.9× Williams-Sonoma, Inc.'s market cap, and Williams-Sonoma, Inc. pays the higher dividend (1.27%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Williams-Sonoma, Inc. for 59 Days on average.
| LLY | WSM | |
|---|---|---|
Market Cap | $1.04T | $28.15B |
Volume | 3,064,878 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $251.81 |
52-Week Low | $799.57 | $168.64 |
Typical Hold Time | 93 Days | 59 Days |
Enterprise Value | $1.09T | $28.65B |
Dividend Yield | 0.59% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
Williams-Sonoma (WSM) trades at $239.00, down 0.61% on the day, with a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.10 surpassing expectations. Profitability remains robust, with a net income margin of 14.73% and ROE of 54.96%. Recent news highlights market share gains and AI integration driving growth.
The outlook is positive, supported by raised full-year guidance and strong operational execution. Key opportunities include margin expansion and dividend growth, while risks involve housing market sensitivity and competitive pressures. Analyst consensus leans bullish with a $246.31 price target, suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
